French Warning of Propecia-Induced Depression and Suicidal Ideation Prompts Wave of Media Attention

by

French Warning of Propecia-Induced Depression and Suicidal Ideation Prompts Wave of Media Attention   Dec. 19, 2017 Dear Friends: France is taking PFS very seriously. On Oct. 26, the French National Agency for Drug Safety (ANSM) issued a warning that “Changes in mood, particularly depression, and suicidal ideation, have been reported by patients taking Propecia.”

European Medicines Agency Recommends Adding Depression and Suicidal Ideation to Finasteride Label

by

Aug. 10, 2017 Dear Friends: On August 4, CEO John Santmann wrote in his 2017 Annual Address, “Recent events in Europe and Asia have given me hope that, before this decade is out, we’ll see the day when no man on earth is prescribed finasteride without ample warning of its many potential dangers.” Then he

2017 PFS Foundation Annual Address

by

2017 Annual Address   Aug. 4, 2017   Dear Friends: Recent events in Europe and Asia have given me hope that, before this decade is out, we’ll see the day when no man on earth is prescribed finasteride without ample warning of its many potential dangers. On May 24, the UK’s equivalent of the US

Korea Mandates Propecia Label Change Based on Reports of Depression and Suicidal Ideation

by

R E G U L A T O R Y   U P D A T E South Korea Mandates Propecia Label Change Based on Reports of Depression and Suicidal Ideation   July 15, 2017 Dear Friends: On July 4, the Korean Ministry of Food and Drug Safety (MFDS) announced it will revise the warning

MHRA Issues Drug Safety Update on Finasteride

by

MHRA Issues Drug Safety Update on Finasteride   UK surveillance agency cites reports of depression and suicidal ideation   May 26, 2017 Dear Friends: The UK’s equivalent of the US Food and Drug Administration, the Medicines and Healthcare Products Regulatory Agency (MHRA), has issued a drug safety update on finasteride. The May 24 document, titled Finasteride:

Peripheral Nervous System Involved in PFS Patients with Severe ED, New Study Demonstrates

by

Peripheral Nervous System Involved in Post-Finasteride Syndrome Patients with Severe Erectile Dysfunction, New Study Demonstrates for the First Time   SOMERSET, N.J., April 18, 2017 – Post-finasteride syndrome (PFS) patients suffer from altered levels of critical brain-function regulators, including neuroactive steroids, according to a new clinical study published in The Journal of Steroid Biochemistry and

Feinberg School of Medicine Epidemiology Study Suggests Tens of Thousands of PFS Cases in Young Men Taking Finasteride for Hair Loss

by

Feinberg School of Medicine Epidemiology Study Suggests Tens of Thousands of Cases of Post-Finasteride Syndrome in Young Men Taking Finasteride for Hair Loss   1.19% of men 16 to 42 years old with no prior history of sexual dysfunction taking low-dose finasteride for more than 205 days developed persistent erectile dysfunction (ED) lasting ≥ 90

‘Underlying Neurobiological Abnormalities’ Exist in Finasteride Users with Persistent Sexual Dysfunction

by

‘Underlying Neurobiological Abnormalities’ Exist in Finasteride Users with Persistent Sexual Dysfunction, Suggests Clinical Study at Brigham and Women’s Hospital   SOMERSET, N.J., Sept. 29, 2016 – Men who experience persistent sexual dysfunction after discontinuing finasteride have “neurobiological abnormalities,” suggests a new study published in The Journal of Clinical Endocrinology & Metabolism. Among those abnormalities is

Support Program Connects PFS Patients Worldwide

by

Support Program Connects PFS Patients Worldwide SOMERSET, N.J., Sept. 9, 2016 – The Post-Finasteride Syndrome Foundation has launched a program to connect PFS patients with one another for mutual support. Any PFS patient or family member of a PFS patient who would like to participate should download the PFS Patient Support form, complete it and

2016 PFS Foundation Annual Address

by

    Aug. 4, 2016   Dear Friends: I began last year’s annual address by letting you know how encouraged I was that the National Institutes of Health had not only added PFS to its Genetic and Rare Diseases Information Center but linked to our website. Now I’m equally encouraged to note a similar milestone,